6une 7 8 9 - era-edta · fc 04 - bone disease in dialysis 09.30 - 10.45 posters, coffee break and...

Programme at a Glance - Sunday, June 7th, 2020

LEGENDA

Fluids and electrolytes, tubular transport,

physiology

Hereditary disorders, development, pregnancy,

paediatric nephrology

Glomerular diseasesand general

clinical nephrology

Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging

End StageRenal Disease

and dialysis

Home therapies, peritoneal

dialysis

Transplantationand

immunology

Hypertension,diabetes,

vascular diseases

Acute Kidney Injuryand intensive care

nephrology

G1 G2A G2B F1 A1 A2 A3 A4 Presentation Theatre08.00 - 09.30 S 01 -

ERA-EDTA RegistryS 02 - Phosphate and FGF23

S 03 - Paediatric Nephrology

S 04 - The many facetsof hypoxia in CKD

FC 01 - Molecular insightin renal pathology

FC 02 - What should CKD patients eat?

FC 03 - Vascular access

FC 04 - Bone diseasein dialysis

09.30 - 10.45 Posters, coffee break and exhibition visitPACE-CME Boehringer Ingelheim/Lilly

Baxter Healthcare Fresenius Medical Care

NxStage Medical AstraZeneca

10.45 - 11.30 PL 1 - Sanjay Jain“Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases”

11.30 - 11.45 Break11.45 - 13.15 S 05 -

Late Breaking Clinical Trials

S 06 -The many faces of monoclonal gammopathy of undetermined significance

S 07 - Improving outcomes in DKD

S 08 - Redefining the ontology of kidney diseases using genomic analysis

S 09 - Brain and nervous system in CKD

FC 05 - Delivery of dialysis: a holistic approach

FC 06 - The next generation of transplant therapeutical approaches

FC 07 - Managing hypertension

13.15 - 14.45 Fresenius Medical Care

Baxter Healthcare Charité-Vifor Fresenius Medical Care Renal Pharma

Novo Nordisk Amgen Europe MundiPharma Sanofi Genzyme Retrophin 13.15-14.00

15.00 - 16.30 S 10 - ASN Highlights

S 11 - ANCA-associated vasculitis

S 12 - Blood pressure targets

S 13 - Precision medicine for the sensitized transplant recipient

FC 08 - Protein energy wasting and inflammation

FC 09 - Novel molecular mechanisms of diabetic nephropathy

FC 10 - Clinical CKD

FC 11 - Improving outcome in dialysis patients

16.30 - 17.00 Posters, coffee break and exhibition visit17.00 - 18.30 S 14 -

Basic immunology and pathology

S 15 - Primary glomerulonephritides

S 16 - Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?

S 17 -Start dialysis? Stop dialysis? - Challenging conversations

FC 12 - Genetics in kidney disease: unravelling complex interactions

FC 13 - Clinical nephrology: predicting outcome

FC 14 - AKI: still difficult to define

FC 15 - Novel discoveries in CKD pathophysiology

ADV - mm 297x40 + 3 mm bleed - PDF/JPGProgramme at a glance 6 7 8 9June

How to use this file...

Click on the dateor arrow to view

the summary table related to a specific day

Click on the LINK barre to view the details

of a specific session within the Virtual

Meeting Programme

Click on the ERA-EDTA logoto go backto the home page.

Click on theVirtual Meeting logoto visit theCongress webpage

TRAC

KS Fluids and electrolytes, tubular transport, physiology




clinical nephrology



and dialysisHome therapies, peritoneal

dialysisTransplantation

andimmunology


vascular diseases


nephrology

Programme at a Glance - Saturday, June 6, 2020

CEPD and Practical Courses DayGold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-3

08:45 - 12:25 PC 1Renal molecular pathology

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 2

CEPD 1Primary & Secondary glomerulo-nephritis, vasculitis, autoimmune diseasesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 1

CEPD 2Hypertension, diabetes, cardiovascular diseases in CKD


CEPD 3CKD and bone mineral disorders in CKD


CEPD 4Onconephrology


PC 2Vascular access

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 112:25 - 13:00 Lunch break13:00 - 16:40 CEPD 5

Haemo- and peritoneal dialysish t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 5

CEPD 6Kidney transplantation


CEPD 7Acute kidney injury


CEPD 8Electrolytes and urolithiasish t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 8

CEPD 9Nephropathology


PC 2Vascular access (repeated)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 1

Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-307:30 - 08:30 ISS 0.1

New Progress of Adsorption Therapy - Jafron Medicalh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 8

08:00 - 08:30

17:00-18:00 Welcome Ceremony + LectureN. Watts“Sustainable healthcare”h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 0

CE

PD

PR

OG

RA

MM

EC

ON

GR

ES

S P

RO

GR

AM

ME

https://www.era-edta.org/en/virtual-meeting/#!contentsessions/46467

Programme at a Glance - Sunday, June 7, 2020

TRAC





clinical nephrology





andimmunology


vascular diseases


nephrology

Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-308:00 - 09:30 S 01

Medicine in the digital age


S 02ADPKD – tolvaptan and beyondh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 2

S 03The inflammatory pathway in CKD: treatments at last?h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 3

S 04ERA-EDTA Registry


FC 01Home dialysis (ML A. Wiecek)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 4

FC 02Novel aspects of nephrolithiasis h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 2

FC 03Prevention of AKI


FC 04Basic science in diabetes

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 409:30 - 10:45 Posters, coffee break and exhibition visit

ISS 1.1Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2iPACE CME - Boheringer Ingelheim/Lillyh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 0 9

ISS 1.2Expert approaches to management across the CKD-MBD continuumVifor Fresenius Medical Care Renal Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 1

ISS 1.3Innovative endpoints for glomerular diseasesRetrophin


ISS 1.4K+: Recurrence, Restriction and FluctuationChange IME - AstraZenecah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 9

10:45 - 11:30 PL 1A. Levey - Chronic kidney dise-ase: two decades of progress and challenges for the futureh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 9

11:30 - 11:45 Break11:45 - 13:15 S 05

Late breaking clinical trials


S 06Advanced renal MRI - the non-invasive renal biopsy in 2020h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 6

S 07Refocussing clinical research in CKD


S 08Towards more home- and self-care


S 09The AKI - AKD - CKD continuum


FC 05Clinical outcomes in transplantation 1 (ML R. Hellemans)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 4

FC 06Hypertension and CKD (ML P. Sarafidis)


FC 07Molecular nephrology (ML B. Dekel)


FC 08Malnutrition in dialysis

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 513:30 - 14:45 ISS 1.5

Optimising RAASi therapy through long-term potas-sium control – opportunities for improved outcomesMedEd Global Solutions - Vifor Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 4

ISS 1.6Dialysis in times of Pandemics: Challenges, Solutions and Lessons Learnt for the FutureFresenius Medical Care


ISS 1.7Improving diabetic kidney disease outcomes: A novel role for GLP-1 receptor agonistsNovo Nordisk


ISS 1.8Understanding the Relationship Between the Mineralocorticoid Receptor and Chronic Kidney Disease in Type 2 DiabetesBayerh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 4 6 8

ISS 1.9Pushing the boundaries of Fabry disease: new insights into diagnosis, immunogeni-city and long-term dataSanofi Genzyme

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 615:00 - 16:30 S 10

ASN Highlights


S 11Green health care in practice


S 12Paediatric nephrology


S 13How to manage maintenance anti-rejection treatment in the pre-sence of relevant co-morbidities?h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 3

FC 09Anaemia management in CKD (ML T. Drueke)


FC 10Clinical nephrology 1(ML G. Gambaro)


FC 11 - Prognosis in haemodialysis(ML V. Jha)


FC 12Exercise in CKD(ML N. Clyne)


FC 13Bone disease in dialysis

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 616:30 - 17:00 Posters, coffee break and exhibition visit17:00 - 18:30 S 14

Combatting kidney disease in Europe: role of European Kidney Health Alliance (EKHA)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 4

S 15The diversified world of nephrology: what the nephrolo-gists do and how renal care is organised in different countriesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 5

S 16Novel tools and target in renal fibrosis


S 17The uraemic syndrome in 2020


FC 14Glomerulonephritis 1 (ML Y. Caliskan + ML G. Moroni)


FC 15Aspects of CKD pathophysiology 1 (ML T. Johnson)


FC 16Cardiovascular diseases in dialysis


FC 17Novelties in cystic disease


SS 1Present situation on COVID-19 in Europe, globally and in nephrology



ISS 1.7Improving diabetic kidney disease outcomes: A novel role for GLP-1 receptor agonistsNovo Nordisk

Programme at a Glance - Monday, June 8, 2020

TRAC





clinical nephrology





andimmunology


vascular diseases


nephrology


Big data and artificial intelligence in renal care


S 19Anaemia treatment in CKD: a changing scenario


S 20Novel diagnostics and treatments for inherited kidney diseases


S 21Ageing kidney and its implications


S 22Sympathetic overactivity as a major trigger of cardiovascular and renal outcomes in CKDh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 2

S 23Dietary approaches in CKD: promoting quality over quantify


FC 18Glomerulonephritis 2 (ML P. Ronco)


FC 19Clinical outcomes in transplantation 2

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 909:30 - 10:45 Posters, coffee break and exhibition visit ERA-EDTA

General Assembly


ISS 2.1Targeting the cause of ANCA Associated Vasculitis - Needs and OutcomesVifor Pharma


ISS 2.2Beyond the kidney: Unexpected causes of renal diseaseTakeda


ISS 2.3Clinical implications of Calcium-Sensing Receptor activationAmgen


ISS 2.4Another kidney stone referral - or a warning of imminent renal failure? How to spot the metabolic diseases that can cause sudden progression to ESRDAlnylam Pharmaceuticalsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 1 3

ISS 2.5Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 raPACE CME - Novo Nordiskh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 1 0

10:45 - 11:30 PL 2P. Romagnani - AKI, CKD and cancer: the costs of kidney repairh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 0

11:30 - 11:45 Break11:45 - 13:15 S 24

Systemic diseases and the kidney


S 25Everyday issues during haemodialysis


S 26Newer outcomes and strate-gies for implementing clinical trials in kidney transplantationh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 6

S 27Current aspects of AKI prevention and treatment


S 28Progress in osteodistrophy and pathways to arterial da-mage and calcification in CKDh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 8

FC 20Clinical nephrology 2 (ML J. Fox)


FC 21Aspects of CKD pathophysiology 2 (ML C. Ferro)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 6

FC 22Health services for renal patients (ML C. Tomson)


FC 23Genetics in nephrology (ML A. Fornoni)

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 1 9 013:30 - 14:45 ISS 2.6

Anaemia of CKD: challenges, underlying mechanisms, and future perspectivesAstellash t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 1 1

ISS 2.7Iron deficiency beyond anaemia in kidney and heart disease - revisiting the cardiorenal syndromeMedEd Global Solutions - Vifor Fresenius Medical Care Renal Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 5

ISS 2.8Clinical Conundrums in aTypical HUSAlexion Pharma


ISS 2.9Genetic Kidney Disease: From innovative diagnosis to new therapeutic targetsSanofi Genzyme


ISS 2.10SGLT2 inhibition in CKD: Our chance to make a differenceChange IME - AstraZenecah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 3

15:00 - 16:30 S 29Expanding the patient’s voice in nephrology with patient outcome measuresh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 9

S 30Mechanisms on CKD progression


S 31PD strategies and outcomes


S 32Wasting in CKD: targeting the muscle


S 33Genetics in kidney disease


FC 24Glomerulonephritis 3(ML J. Floege)


FC 25CKD and nutrition (ML P. Molina)


FC 26Clinical diabetic nephropathy (ML K. Turkmen)


FC 27Revisiting the bone in CKD

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 0 0 016:30 - 17:00 Posters, coffee break and exhibition visit17:00 - 18:30 S 34

The hypertension spectrum in CKD: pathophysiology and risk


S 35Environmental threats to kidney health


S 36Sodium and human disease


S 37Electrolytes and acid-base for the future


FC 28Nephropathology insights (ML E. McQuarries)


FC 29Experimental AKI (ML M. Nangaku)


FC 30CKD epidemiology (ML G. Parati)


FC 31Paediatric nephrology (ML F. Emma)


SS 2Acute kidney injury, dialysis and transplantation in patients tested COVID-19 positiveh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 6 1


Programme at a Glance - Tuesday, June 9, 2020

TRAC





clinical nephrology





andimmunology


vascular diseases


nephrology


Cardiovascular and renal protection - effects of SGLT2 inhibitors and GLP-1 receptor agonists in people with CKD and type 2 diabetesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 8

S 39New immune therapies and onconephrology


S 40Cognitive impairment in CKD


FC 32Experimental transplantation (ML M. Essig)


FC 33Extracorporeal treatment of ESKD


FC 34Outcome after AKI

h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 0 0 210:00 - 10:15 Break10:15 - 11:00 PL 3

B. StaelsCircadian control of metabolism and inflammation and pathological consequences of clock perturbationsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 8

11:15 - 12:45 SS 3Nephrology Pearlsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 6 9


www.era-edta.org

6une 7 8 9 - era-edta · fc 04 - bone disease in dialysis 09.30 - 10.45 posters, coffee break and...

Documents